BLCO Bausch & Lomb Corp
Ophthalmic Goods · NYSE · SEC CIK 1860742 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.9%
TTM net income YoY63.6%
TTM EPS YoY62.8%
Revenue 3-yr CAGR10.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin7.1%
Net margin-2.0%
FCF margin4.7%
EBITDA margin14.5%
Returns
ROE-1.7%
ROA-0.8%
ROIC (approx.)2.8%
Asset turnover0.39x
Leverage & solvency
Liabilities / assets53.4%
Debt / equity0.78x
Current ratio1.56x
Interest coverage1.00x
Cash quality & payout
Operating cash flow / net income-4.99x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5.10B | $4.79B |
| R&D expense | $371.00M | $343.00M |
| SG&A expense | $2.23B | $2.08B |
| Operating income | $113.00M | $162.00M |
| Interest expense | $421.00M | $399.00M |
| Pretax income | -$317.00M | -$234.00M |
| Income tax | $35.00M | $71.00M |
| Net income | -$360.00M | -$317.00M |
| EBITDA | $534.00M | $598.00M |
| EPS (basic) | -1.02 | -0.90 |
| EPS (diluted) | -1.02 | -0.90 |
| Weighted avg. shares (diluted) | 353.80M | 351.80M |
| Balance sheet | ||
| Cash & equivalents | $383.00M | $316.00M |
| Receivables | $1.22B | $1.03B |
| Inventory | $976.00M | $1.04B |
| Current assets | $2.98B | $2.79B |
| PP&E, net | $1.76B | $1.49B |
| Goodwill | $4.76B | $4.52B |
| Intangibles | $3.28B | $3.49B |
| Total assets | $14.02B | $13.47B |
| Current liabilities | $1.92B | $1.74B |
| Short-term debt | $28.00M | $40.00M |
| Long-term debt | $5.02B | $4.74B |
| Total debt | $5.05B | $4.78B |
| Total liabilities | $7.50B | $6.92B |
| Shareholders' equity | $6.45B | $6.47B |
| Net debt | $4.67B | $4.47B |
| Shares outstanding | 354.21M | 352.40M |
| Cash flow statement | ||
| Operating cash flow | $283.00M | $232.00M |
| Capital expenditure | $349.00M | $291.00M |
| Free cash flow | -$66.00M | -$59.00M |
| Investing cash flow | -$455.00M | -$412.00M |
| Financing cash flow | $225.00M | $178.00M |
| Depreciation & amortization | $421.00M | $436.00M |
| Stock-based compensation | $149.00M | $92.00M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.